Back to search

Aristotle University Of Thessaloniki (AUTH)

Η επίδραση της θεραπείας με μετφορμίνη στα επίπεδα των κυτταροκινών σε γυναίκες με σύνδρομο πολυκυστικών ωοθηκών

Abstract

dc:description

Introduction: Over a third of women with polycystic ovary syndrome (PCOS) display glucose intolerance and multiple risk factors for cardiovascular disease, including central obesity and insulin resistance. Cytokines like interleukin-6 (IL-6) and TNF-• and inflammatory markers like CRP and MCP-1 have recently been implicated as important links in the development of cardiovascular disease in human obesity and type 2 Diabetes. Metformin, an oral euglycaemic agent, is used as treatment for women with PCOS and provides a model to study cytokine regulation. Subjects and Methods: We determined circulating levels of inflammatory markers (hs-CRP and MCP-1) and Cytokines (IL-6, sTNFRI and sTNFRII, leptin and adiponectin) in 59 women (mean BMI: 26.9±5.9 kg/m²; age: 29±5.1 years) with PCOS of whom 37 were retested after receiving a therapeutic trial of Metformin (1500 mg/day) for 6 weeks and 6 months. In this way, we could study the response of adipose tissue-derived cytokines and inflammatory markers to weight loss and insulin sensitization. Fasting metabolic and hormone profiles were also recorded. Thirty six healthy women who were closely matched for BMI and age comprise the control group. Results: Lean women with PCOS had higher LH and Androstenedione and lower adiponectin levels (p=0.03) compared to lean controls. Obese women with PCOS had higher LH, Androstenedione and IL-6 levels (p=0.04) = 0.004) compared to obese controls. IL-6 levels correlated significantly with measures of adiposity (BMI r=0.55, p<0.001) and indices of insulin resistance (fasting insulin r=0.42, p=0.002; HOMA-R r=0.47 p<0.001). A very strong association was found between IL-6 and hs-CRP levels (r=0.59, p<0.001). However, adiposity as well as insulin resistance seems to account for most of the variability of IL-6 in women with PCOS. While there was a close association between CRP and BMI and HOMA-R, IL-6 was mainly regulated hs-CRP with the independent contribution of insulin resistance. In a subset of lean and obese patients (total n=37; Obese=25; Lean=12) 6 weeks of metformin therapy produced a significant reduction in BMI (p<0.001), waist (p<0.001), hs-CRP (p<0.01), MCP-1 (p=0.03) and leptin levels (p=0.03), but not in IL-6, sTNF-RI & sTNF-RII or adiponectin levels. Six months of metformin therapy compared to baseline produced reduction in BMI (p<0.001) and waist (p=0.001), HOMA-R (p=0.01), IL6 (p=0.002), sTNF-RII (p=0.05) and leptin levels (p=0.004), which were statistically significant, but not in hsCRP, MCP -1 or adiponectin levels. Conclusions: Our findings suggest that in women with PCOS obesity as well as insulin resistance is the main determinants of IL-6. The variability of hs-CRP is most strongly accounted with IL-6 levels with the independent contribution of insulin resistance. Metformin therapy facilitates weight loss, which is reflected by a reduction in hs-CRP, MCP-1 and leptin levels short-term and a reduction of IL-6, sTNFRII, HOMA-R and leptin levels long-term. It seems likely that fat mass reduction has to reach a particular level before changes in adipose tissue-derived cytokine levels become apparent. Metformin-induced reduction of hs-CRP levels prior to any significant changes in insulin resistance or IL-6 may involve different mechanisms of action. Finally, the anti-inflammatory properties of metformin may explain, at least in part, its cardio protective effects.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsilchorozidou, T.
  • Τσιλχοροζίδου, Τασούλα

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/19370

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsilchorozidou, T.; Τσιλχοροζίδου, Τασούλα. Η επίδραση της θεραπείας με μετφορμίνη στα επίπεδα των κυτταροκινών σε γυναίκες με σύνδρομο πολυκυστικών ωοθηκών. Aristotle University Of Thessaloniki (AUTH), 2008. http://hdl.handle.net/10442/hedi/19370